Clinical trials: Glucose Tolerance
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
Impaired Glucose Tolerance, Oxidative Stress
Effect of Dietary Glycemic Index on Beta-cell Function
The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for…
- Conditions
- Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
- Trial name
- GIdiet (NCT01386645)
- Testing
- low glycemic index (LGI) diet, high glycemic index diet plus N-acetylcysteine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Hypertension
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.
- Trial name
- NCT00673790
- Testing
- Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril
- Where
- 88 sites in United States
- Volunteers
- 537 people
- Sponsor
- Forest Laboratories
Diabetes Mellitus, Type 1
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the…
- Trial name
- TN07 (NCT00419562)
- Testing
- Oral Insulin
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 560 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Diseases
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
- Trial name
- NCT04958109
- Testing
- Oral Glucose Tolerance Test, Kisspeptin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Chronic Kidney Disease
Metabolic Effects of Paricalcitol
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).
- Trial name
- NCT01003275
- Testing
- Paricalcitol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Insulin Resistance
The Effects of Altering Physical Activity on Cardiometabolic Health
The effects of physical inactivity on variations in blood glucose and vascular health are not fully understood. The purpose of this study is to determine if an acute transition from physical activity to inactivity alters vascular…
- Trial name
- PIA (NCT01879059)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Obese, Diabetes Mellitus, Type 2
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
The investigators will recruit obese subjects with pre-diabetes or type 2 diabetes for the proposed clinical study for 5 visits.
- Trial name
- NCT03991299
- Testing
- Botox 200 UNT Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Impaired Glucose Tolerance
Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Purpose of the study: to assess the efficacy of Subetta in the treatment of impaired glucose tolerance to assess the safety of Subetta in the treatment of impaired glucose tolerance.
- Trial name
- NCT03725033
- Testing
- Subetta
- Where
- 44 sites in Russia
- Volunteers
- 538 people
- Sponsor
- Materia Medica Holding
Type 2 Diabetes Mellitus
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
The main goals of the study are to evaluate the effect of Exenatide on endothelial-dependent vasodilation, as measured by flow mediated dilation (FMD), to evaluate the effect on endothelial-independent vasodilation, as measured…
- Trial name
- NCT00353834
- Testing
- Exenatide, Glargine Insulin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Joslin Diabetes Center
Obesity, Morbid
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy.
- Trial name
- NCT00886626
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Impaired Glucose Tolerance (IGT)
Postmarketing Clinical Study on AO-128
The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose) 0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to diet therapy and exercise therapy, and…
- Trial name
- NCT02287402
- Testing
- AO-128
- Volunteers
- 197 people
- Sponsor
- Takeda
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Pre-diabetes
Vitamin D in Minorities With Prediabetes
Vitamin D supplementation in minority subjects with both pre-diabetes and low vitamin D levels will delay the development of diabetes.
- Trial name
- NCT00876928
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Charles Drew University of Medicine and Science
Insulin Resistance, Diabetes Mellitus
A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers
The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers.
- Trial name
- NCT00741026
- Testing
- Olanzapine 10 mg po qhs for 3 days
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance.
- Trial name
- Elevage (NCT03980730)
- Testing
- Azeliragon
- Where
- 33 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- vTv Therapeutics
Impaired Glucose Tolerance
Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others.
- Trial name
- NCT02621060
- Testing
- Chlorogenic acid
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara
Type 2 Diabetes
Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes
The purpose of this study is to determine if 2 weeks of nightly exposure (7-12 hours per night) to moderate hypoxia (~2,400 meters or 7,500 feet) improves glucose metabolism in people with type 2 diabetes.
- Trial name
- SLEEPDM (NCT02513641)
- Testing
- Hypoxico Altitude Training Systems
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center